<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323360</url>
  </required_header>
  <id_info>
    <org_study_id>1315</org_study_id>
    <nct_id>NCT02323360</nct_id>
  </id_info>
  <brief_title>A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC</brief_title>
  <official_title>A Randomised Phase III Trial on Stereotactic Body Radiotherapy (SBRT) After Incomplete Transcatheter Arterial Embolization (TAE) or Chemoembolization (TACE) Versus Exclusive TAE or TACE for Inoperable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group
      superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable
      HCC treated with a TAE/TACE incomplete cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase III study patients with inoperable HCC single nodule no more 5 cm or 1- 3
      nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic
      radiotherapy in 3 or 6 daily fractions or to a new cycle of TAE or TACE. A total of 80
      patients (40 in each arm) will be recruited into the trial over a 2 years period and will be
      randomised on an equal basis to either SBRT or TAE/TACE. The follow-up period will be
      finished 1.5 years after the final patient is randomised.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    too slow enrollment
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE)</measure>
    <time_frame>1.5 years</time_frame>
    <description>This is a study designed to evaluate the efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free-survival</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity (incidence of acute and late complications)</measure>
    <time_frame>1.5 years</time_frame>
    <description>incidence of acute and late complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCC after incomplete TAE or TACE treated by SBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE/TAE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions</description>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <other_name>Stereotactic body radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE</description>
    <arm_group_label>TACE/TAE</arm_group_label>
    <other_name>Transcatheter arterial chemoembolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Karnofsky index &gt;70%

          -  Child-Turgotte-Pugh A or B liver score.

          -  An initial diagnosis of primary HCC or recurrence.

          -  A technically unresectable lesion or medically contraindicated surgery or a case in
             which surgery was declined.

          -  HCC (single nodule ≤ 5 cm or max 3 nodules ≤ 3 cm) diagnosed by histology or
             non-invasive EASL criteria

          -  Baseline CT or MRI and bone scan without evidence of radiologically definable major
             vascular invasion or extrahepatic disease

          -  Hb &gt;10.5.0 g/%, WBC &gt;3.000 cells/mm3, platelets &gt;50.000 cells/mm3, bilirubin &lt;2 mg/dl,
             aspartate and alanine aminotransferase levels &lt;5 times upper normal limit, and
             prothrombin time-international normalized ratio ≤ 2;

          -  Serum creatinine &lt;1.7 mg/dl

          -  Previously incomplete TAE or TACE with radiologically defined residual disease.

          -  Informed consent

        Exclusion Criteria:

          -  Extrahepatic disease and refractory ascites.

          -  Previous abdominal radiation therapy (RT)

          -  Hemorrhage/bleeding event = Grade 3 within 4 weeks of enrollment in the study.

          -  Pregnant or breastfeeding patients.

          -  Patients with uncontrolled infections or HIV seropositive patients.

          -  Mental conditions rendering the patient incapable to understand the nature, scope, and
             consequences of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>TACE</keyword>
  <keyword>TAE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

